GAST KEVIN – Trademark Portfolio
Entity Type: 01
GAST KEVIN holds 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 7 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 5 Nice Classification classes. Currently, 8 trademarks are registered. Notable registered marks include DIACLIN, ZEROTOX, GAST USA, ABX PHARMA, and GOOD MORNING. The owner is based in Pretoria.
Private Bag X6
Faerie Glen
Pretoria 0043 , ZA
Showing of trademarks Trademarks
Trademark Classifications
GAST KEVIN's trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does GAST KEVIN have?
GAST KEVIN has 10 U.S. trademarks filed with the USPTO. Of these, 8 registered, 2 abandoned.
What trademark classes does GAST KEVIN file in?
GAST KEVIN files trademarks across 5 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business), Class 37 (Building & Construction), Class 42 (Computer & Scientific), Class 40 (Treatment & Processing). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are GAST KEVIN's most well-known trademarks?
GAST KEVIN's registered trademark portfolio includes well-known marks such as DIACLIN, ZEROTOX, GAST USA, ABX PHARMA, and GOOD MORNING. These are among 8 currently registered trademarks in the portfolio.
What is GAST KEVIN's trademark registration success rate?
GAST KEVIN has a 80% trademark registration rate, with 8 out of 10 resolved applications resulting in successful registration. Currently, 0 applications are pending review.